Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ
Currency in USD
108.24
+1.19(+1.11%)
Closed·
After Hours
107.99-0.25(-0.23%)
·
JAZZ Scorecard
Full Analysis
Management has been aggressively buying back shares
JAZZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
106.56109.43
52 wk Range
95.49148.06
Key Statistics
Edit
Prev. Close
107.05
Open
106.94
Day's Range
106.56-109.43
52 wk Range
95.49-148.06
Volume
601.59K
Average Volume (3m)
1.24M
1-Year Change
-6.53%
Book Value / Share
68.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
JAZZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
188.63
Upside
+74.27%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Jazz Pharmaceuticals PLC News & Analysis

Show more

Jazz Pharma Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Employees
2800

Compare JAZZ to Peers and Sector

Metrics to compare
JAZZ
Peers
Sector
Relationship
P/E Ratio
13.6x0.3x−0.5x
PEG Ratio
0.27−0.650.00
Price/Book
1.6x6.2x2.6x
Price / LTM Sales
1.6x3.8x3.0x
Upside (Analyst Target)
72.7%64.3%51.5%
Fair Value Upside
Unlock24.6%9.4%Unlock

Analyst Ratings

16 Buy
1 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 188.63
(+74.27% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
1.68 / 4.81
Revenue / Forecast
897.84M / 983.86M
EPS Revisions
Last 90 days

People Also Watch

105.45
TOL
+0.57%
127.31
NBIX
+1.95%
17.06
ZTO
-0.96%
21.56
GMAB
-2.13%
64.84
PVH
+1.12%

FAQ

What Is the Jazz Pharma (JAZZ) Stock Price Today?

The Jazz Pharma stock price today is 108.24

What Stock Exchange Does Jazz Pharma Trade On?

Jazz Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Jazz Pharma?

The stock symbol for Jazz Pharma is "JAZZ."

What Is the Jazz Pharma Market Cap?

As of today, Jazz Pharma market cap is 6.54B.

What Is Jazz Pharma's Earnings Per Share (TTM)?

The Jazz Pharma EPS (TTM) is 7.85.

When Is the Next Jazz Pharma Earnings Date?

Jazz Pharma will release its next earnings report on 29 Jul 2025.

From a Technical Analysis Perspective, Is JAZZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Jazz Pharma Stock Split?

Jazz Pharma has split 0 times.

How Many Employees Does Jazz Pharma Have?

Jazz Pharma has 2800 employees.

What is the current trading status of Jazz Pharma (JAZZ)?

As of 18 Jun 2025, Jazz Pharma (JAZZ) is trading at a price of 108.24, with a previous close of 107.05. The stock has fluctuated within a day range of 106.56 to 109.43, while its 52-week range spans from 95.49 to 148.06.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.